Tags

Type your tag names separated by a space and hit enter

Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
Ann Neurol. 1995 Jan; 37(1):95-8.AN

Abstract

The long-term effect of selegiline (L-deprenyl) in the treatment of Parkinson's disease has not been clearly delineated. We report on a group of patients whose treatment was initiated with selegiline (n = 43) and then subsequently included L-dopa-carbidopa (Sinemet) and in whom an extended period of observation was carried out; they are compared to a group of patients whose treatment consisted of L-dopa-carbidopa alone (n = 39). In each, serial observations of the parkinsonian state and the response to treatment on a yearly basis for a period of 5 years were performed. No significant difference in the Hoehn-Yahr stage or in the motor subscores of tremor, rigidity, bradykinesia, and gait-posture was found between the two groups, nor was there a significant difference in the incidence of fluctuating responses or dyskinesias. The group that received combination therapy required less L-dopa than did the group that received L-dopa-carbidopa alone during the first 3 years of treatment and a similar trend was evident in years 4 to 5. We conclude that minimal benefits accrued to the parkinsonian patients from long-term use of selegiline. No clinical evidence to support the claim of "neuroprotective" properties was found. Selegiline's major usefulness is to modify the fluctuating therapeutic response seen with L-dopa-carbidopa.

Authors+Show Affiliations

Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029.No affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

7818264

Citation

Brannan, T, and M D. Yahr. "Comparative Study of Selegiline Plus L-dopa-carbidopa Versus L-dopa-carbidopa Alone in the Treatment of Parkinson's Disease." Annals of Neurology, vol. 37, no. 1, 1995, pp. 95-8.
Brannan T, Yahr MD. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Ann Neurol. 1995;37(1):95-8.
Brannan, T., & Yahr, M. D. (1995). Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Annals of Neurology, 37(1), 95-8.
Brannan T, Yahr MD. Comparative Study of Selegiline Plus L-dopa-carbidopa Versus L-dopa-carbidopa Alone in the Treatment of Parkinson's Disease. Ann Neurol. 1995;37(1):95-8. PubMed PMID: 7818264.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. AU - Brannan,T, AU - Yahr,M D, PY - 1995/1/1/pubmed PY - 1995/1/1/medline PY - 1995/1/1/entrez SP - 95 EP - 8 JF - Annals of neurology JO - Ann Neurol VL - 37 IS - 1 N2 - The long-term effect of selegiline (L-deprenyl) in the treatment of Parkinson's disease has not been clearly delineated. We report on a group of patients whose treatment was initiated with selegiline (n = 43) and then subsequently included L-dopa-carbidopa (Sinemet) and in whom an extended period of observation was carried out; they are compared to a group of patients whose treatment consisted of L-dopa-carbidopa alone (n = 39). In each, serial observations of the parkinsonian state and the response to treatment on a yearly basis for a period of 5 years were performed. No significant difference in the Hoehn-Yahr stage or in the motor subscores of tremor, rigidity, bradykinesia, and gait-posture was found between the two groups, nor was there a significant difference in the incidence of fluctuating responses or dyskinesias. The group that received combination therapy required less L-dopa than did the group that received L-dopa-carbidopa alone during the first 3 years of treatment and a similar trend was evident in years 4 to 5. We conclude that minimal benefits accrued to the parkinsonian patients from long-term use of selegiline. No clinical evidence to support the claim of "neuroprotective" properties was found. Selegiline's major usefulness is to modify the fluctuating therapeutic response seen with L-dopa-carbidopa. SN - 0364-5134 UR - https://www.unboundmedicine.com/medline/citation/7818264/Comparative_study_of_selegiline_plus_L_dopa_carbidopa_versus_L_dopa_carbidopa_alone_in_the_treatment_of_Parkinson's_disease_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0364-5134&date=1995&volume=37&issue=1&spage=95 DB - PRIME DP - Unbound Medicine ER -